(object) array( 'id' => '10479592', 'url' => 'FR/amino_acids_₁₂', 'image' => '', 'title' => 'Acides aminés', 'tags' => array ( 0 => 'Acides aminés', 1 => 'Beauty', 2 => 'Skin care', 3 => '', ), 'term' => 'Acides aminés', 'source_id' => 5094749, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Beauty', ), 'category' => array ( 0 => 'Skin care', ), 'lastedit' => '20150728083421', 'part_of_speech' => 'noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'Les blocs de construction des protéines qui composent collagène et d\'élastine-substances qui donnent à la peau son soutien structurel. Le vieillissement et une combinaison de facteurs externes (dont la lumière UV et les toxines environnementales) réduisent le niveau des acides aminés dans le corps ; les crèmes contenant des acides aminés peuvent aider à les restaurer.', 'usage_comment' => '', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1507928310838984707, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Definition' => 'The building blocks of the proteins that make up collagen and elastin—substances that give the skin its structural support. Aging and a combination of external factors (including UV light and environmental toxins) reduce the level of amino acids in the body; creams containing amino acids may help restore them.', 'Part of Speech' => 'noun', 'Industry' => 'Beauty', 'Product Category' => 'Skin care', 'Creation User' => 'MaryK', 'Creation Date' => '2013/3/16', 'Term' => 'amino acids', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'amino_acids_₁₂', )

(object) array( 'id' => '3951178', 'url' => 'FR/superbug', 'image' => 'Superbug.jpg;', 'title' => 'Superbactéries', 'tags' => array ( 0 => 'Superbactéries', 1 => 'Pharmaceutical', 2 => '', ), 'term' => 'Superbactéries', 'source_id' => 275134, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Pharmaceutical', ), 'lastedit' => '20150721084102', 'part_of_speech' => 'noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'Bactéries résistantes à presque tous les antibiotiques. Les gènes peuvent être transférés entre les bactéries par conjugaison, transduction ou transformation. Cela signifie que les gènes de résistance aux antibiotiques peuvent se lier à de nombreux types de germes courants et leur confèrent une importante résistance aux médicaments, en créant de superbactéries dangereuses. La dernière épidémie de superbactéries implique des patients qui ont voyagé en Inde où il y a une surpopulation et un usage excessif établi des antibiotiques. Beaucoup de gens en Inde manquent également d\'eau potable et ont des diarrhées répandues ; ce sont des conditions idéales pour la création de superbactéries.', 'usage_comment' => '', 'glossary' => '', 'width' => 450, 'height' => 362, '_version_' => 1507294573051772929, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Term' => 'superbug', 'Definition' => 'Bacteria resistant to nearly all antibiotics. Genes can be transferred between bacteria by conjugation, transduction, or transformation. This means antibiotic resistance genes can hitch onto many types of common germs and confers broad drug resistance, creating dangerous superbugs. The latest outbreak of superbugs involve patients who have travel to India with an overpopulation and documented overuses antibiotics. Many people in India also lack clean water and have widespread diarrhea disease, which are ideal conditions for the creation of the superbug', 'Part of Speech' => 'noun', 'Usage Status' => 'New', 'Synonym' => 'super bacteria_₀; super bug_₀', 'Sample Image' => 'Superbug.jpg;', 'Industry' => 'Pharmaceutical', 'Domain' => 'Documentation; Marketing', 'Other Reference' => 'TIN', 'Creation User' => 'Bethsm', 'Creation Date' => '2010/9/14', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'superbug', )

(object) array( 'id' => '6877605', 'url' => 'FR/Angiotensin_II_Receptor_Blockers_(ARBs)', 'image' => '', 'title' => 'Antagonistes des récepteurs de l\'angiotensine II (ARA II)', 'tags' => array ( 0 => 'Antagonistes des récepteurs de l\'angiotensine II (ARA II)', 1 => 'Pharmaceutical', 2 => 'Drugs', 3 => '', ), 'term' => 'Antagonistes des récepteurs de l\'angiotensine II (ARA II)', 'source_id' => 1038764, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Drugs', ), 'lastedit' => '20150721084107', 'part_of_speech' => 'proper noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'Médicaments qui bloquent l\'action de l\'angiotensine II en l\'empêchant de se lier à des récepteurs de l\'angiotensine II sur les vaisseaux sanguins.', 'usage_comment' => '', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1507294573051772930, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Term' => 'Angiotensin II Receptor Blockers (ARBs)', 'Definition' => 'Medications that block the action of angiotensin II by preventing angiotensin II from binding to angiotensin II receptors on blood vessels.', 'Part of Speech' => 'proper noun', 'Usage Status' => 'New', 'Industry' => 'Pharmaceutical', 'Product Category' => 'Drugs', 'Creation User' => 'CCTRADUCTION', 'Creation Date' => '2011/4/12', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'Angiotensin_II_Receptor_Blockers_(ARBs)', )

(object) array( 'id' => '10479591', 'url' => 'FR/actinic_keratoses_₂', 'image' => '', 'title' => 'Kératose actinique', 'tags' => array ( 0 => 'Kératose actinique', 1 => 'Beauty', 2 => 'Skin care', 3 => '', ), 'term' => 'Kératose actinique', 'source_id' => 5092398, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Beauty', ), 'category' => array ( 0 => 'Skin care', ), 'lastedit' => '20150728083418', 'part_of_speech' => 'noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'Lésions précancéreuses se traduisant par une zone rouge, épaisse et rugueuse ; elles apparaissent habituellement sur une peau endommagée par le soleil.', 'usage_comment' => '', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1507928310838984706, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Definition' => 'Precancerous growths that can appear red, thick, and rough; usually found on sun-damaged skin.', 'Part of Speech' => 'noun', 'Industry' => 'Beauty', 'Product Category' => 'Skin care', 'Creation User' => 'MaryK', 'Creation Date' => '2013/3/15', 'Term' => 'actinic keratoses', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'actinic_keratoses_₂', )

(object) array( 'id' => '6227765', 'url' => 'FR/inclusion_criteria', 'image' => '', 'title' => 'Critères d\'inclusion', 'tags' => array ( 0 => 'Critères d\'inclusion', 1 => 'Medical devices', 2 => 'Pharmaceutical', 3 => 'Clinical trials', 4 => 'National Library of Medicine', 5 => '', ), 'term' => 'Critères d\'inclusion', 'source_id' => 4010895, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Medical devices', 1 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Clinical trials', ), 'company' => array ( 0 => 'National Library of Medicine', ), 'lastedit' => '20150722105913', 'part_of_speech' => 'noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'Les facteurs ou les raisons qui autorisent une personne à participer à une étude clinique.', 'usage_comment' => '', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1507393851745107969, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Company' => 'National Library of Medicine', 'Definition' => 'The factors or reasons that allow a person to participate in a clinical study.', 'Industry' => 'Medical devices; Pharmaceutical', 'Part of Speech' => 'noun', 'Product Category' => 'Clinical trials', 'Creation User' => 'elighy', 'Creation Date' => '2012/10/13', 'Term' => 'inclusion criteria', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'inclusion_criteria', )

(object) array( 'id' => '7745836', 'url' => 'FR/informed_consent_₇', 'image' => '', 'title' => 'Consentement éclairé', 'tags' => array ( 0 => 'Consentement éclairé', 1 => 'Pharmaceutical', 2 => 'Clinical trials', 3 => '', ), 'term' => 'Consentement éclairé', 'source_id' => 1259720, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Clinical trials', ), 'lastedit' => '20150721084111', 'part_of_speech' => 'noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'Un processus afin de s\'assurer que les patients volontaires comprennent tous les risques associés à la participation à un essai clinique tels que les effets indésirables et choisissent de participer sans coercition ni pression de quiconque. Le chercheur principal ou de ses associés sont tenus d\'expliquer l\'étude attentivement et répondre à toutes les questions d\'un participant avant l\'essai clinique.', 'usage_comment' => '', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1507294573052821505, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Term' => 'informed consent', 'Definition' => 'A process to ensure that patient volunteers understand all the risks associated participating in a clinical trial such as adverse side effects and are choosing to participate without coercion or pressure from anyone. The principal investigator or his or her associates are required to explain the study carefully and answer all questions of a participant before the clinical trial.', 'Part of Speech' => 'noun', 'Usage Status' => 'New', 'Industry' => 'Pharmaceutical', 'Product Category' => 'Clinical trials', 'Creation User' => 'John Martin', 'Creation Date' => '2011/5/16', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'informed_consent_₇', )

(object) array( 'id' => '6227764', 'url' => 'FR/sponsor_investigator', 'image' => '', 'title' => 'Sponsor-investigateur', 'tags' => array ( 0 => 'Sponsor-investigateur', 1 => 'Medical devices', 2 => 'Pharmaceutical', 3 => 'Clinical trials', 4 => 'National Library of Medicine', 5 => '', ), 'term' => 'Sponsor-investigateur', 'source_id' => 4010894, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Medical devices', 1 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Clinical trials', ), 'company' => array ( 0 => 'National Library of Medicine', ), 'lastedit' => '20150722105912', 'part_of_speech' => 'noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'La personne qui initie et conduit l\'étude clinique.', 'usage_comment' => '', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1507393851745107968, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Company' => 'National Library of Medicine', 'Definition' => 'The person who both initiates and conducts the clinical study.', 'Industry' => 'Medical devices; Pharmaceutical', 'Part of Speech' => 'noun', 'Product Category' => 'Clinical trials', 'Creation User' => 'elighy', 'Creation Date' => '2012/10/13', 'Term' => 'sponsor investigator', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'sponsor_investigator', )

(object) array( 'id' => '6229774', 'url' => 'FR/clinical_trial_₁₁', 'image' => '', 'title' => 'Essai clinique', 'tags' => array ( 0 => 'Essai clinique', 1 => 'Medical devices', 2 => 'Pharmaceutical', 3 => 'Clinical trials', 4 => 'National Library of Medicine', 5 => '', ), 'term' => 'Essai clinique', 'source_id' => 4011597, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Medical devices', 1 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Clinical trials', ), 'company' => array ( 0 => 'National Library of Medicine', ), 'lastedit' => '20150727104712', 'part_of_speech' => 'noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'Une étude clinique dans laquelle les participants sont assignés à recevoir une ou plusieurs interventions (ou pas d\'intervention) afin que les chercheurs puissent évaluer les effets des interventions sur les résultats biomédicaux ou liés à la santé. Les assignations sont déterminées par le protocole d\'étude. Les participants peuvent recevoir des interventions diagnostiques, thérapeutiques ou d\'autres types d\'interventions.', 'usage_comment' => '', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1507846081755480064, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Company' => 'National Library of Medicine', 'Definition' => 'A clinical study in which participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes. The assignments are determined by the study protocol. Participants may receive diagnostic, therapeutic, or other types of interventions.', 'Industry' => 'Medical devices; Pharmaceutical', 'Part of Speech' => 'noun', 'Product Category' => 'Clinical trials', 'Synonym' => 'interventional_study', 'Creation User' => 'elighy', 'Creation Date' => '2012/10/13', 'Term' => 'clinical trial', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'clinical_trial_₁₁', )

(object) array( 'id' => '6229325', 'url' => 'FR/informed_consent_₁₂', 'image' => '', 'title' => 'Consentement éclairé', 'tags' => array ( 0 => 'Consentement éclairé', 1 => 'Medical devices', 2 => 'Pharmaceutical', 3 => 'Clinical trials', 4 => 'National Library of Medicine', 5 => '', ), 'term' => 'Consentement éclairé', 'source_id' => 4011444, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Medical devices', 1 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Clinical trials', ), 'company' => array ( 0 => 'National Library of Medicine', ), 'lastedit' => '20150727104711', 'part_of_speech' => 'noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'Un processus dans lequel les chercheurs communiquent avec les participants potentiels et inscrits dans une étude clinique. Ceci est lorsque les chercheurs : # fournissent toutes les informations importantes concernant l\'étude, de sorte que les participants potentiels peuvent décider de s\'y inscrire (ou si elles sont inscrites, de continuer à participer) ; # s\'assurent que les participants potentiels comprennent les risques et les bénéfices potentiels de participer à l\'étude, et les alternatives à l\'étude conduite ; et # soulignent que l\'inscription à une étude clinique (et de rester dedans) est entièrement volontaire. Parce que donner son consentement pour participer à la recherche n\'est pas un contrat, les participants peuvent quitter une étude à tout moment. Le but du processus de consentement éclairé est de protéger les participants. Il commence quand un participant potentiel demande au début des informations sur une étude et continue tout au long de l\'étude jusqu\'à ce que l\'étude se termine. Le chercheur et le participant potentiel ont des discussions qui incluent de répondre aux questions des participants sur la recherche. Toutes les informations importantes à propos de l\'étude doivent également être remises au participant potentiel dans un document écrit qui est clair et facile à comprendre. Ce document de consentement éclairé est examiné et approuvé par le Comité de protection des personnes pour chaque étude avant d\'être remis aux participants potentiels. Généralement, une personne doit signer un document de consentement éclairé pour s\'inscrire dans une étude.', 'usage_comment' => '', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1507846081754431490, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Company' => 'National Library of Medicine', 'Definition' => 'A process in which researchers communicate with potential and enrolled participants about a clinical study. This is when researchers: # provide all the important information about the study, so that potential participants can decide whether to enroll (or if enrolled, to continue participating); # ensure that potential participants understand the risks and potential benefits of participating in the study, and the alternatives to the research being conducted; and # stress that enrolling in (and staying in) a clinical study is completely voluntary. Because giving consent to participate in research is not a contract, participants can leave a study at any time. The goal of the informed consent process is to protect participants. It begins when a potential participant first asks for information about a study and continues throughout the study until the study ends. The researcher and potential participant have discussions that include answering the participant\'s questions about the research. All the important information about the study must also be given to the potential participant in a written document that is clear and easy to understand. This informed consent document is reviewed and approved by the human subjects review board for a study before it is given to potential participants. Generally, a person must sign an informed consent document to enroll in a study.', 'Industry' => 'Medical devices; Pharmaceutical', 'Part of Speech' => 'noun', 'Product Category' => 'Clinical trials', 'Creation User' => 'elighy', 'Creation Date' => '2012/10/13', 'Term' => 'informed consent', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'informed_consent_₁₂', )

(object) array( 'id' => '6228059', 'url' => 'FR/single_blind_masking', 'image' => '', 'title' => 'Etude en simple aveugle', 'tags' => array ( 0 => 'Etude en simple aveugle', 1 => 'Medical devices', 2 => 'Pharmaceutical', 3 => 'Clinical trials', 4 => 'National Library of Medicine', 5 => '', ), 'term' => 'Etude en simple aveugle', 'source_id' => 4011054, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Medical devices', 1 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Clinical trials', ), 'company' => array ( 0 => 'National Library of Medicine', ), 'lastedit' => '20150722105915', 'part_of_speech' => 'noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'Un type d\'étude en aveugle dans laquelle une partie impliquée dans l\'essai clinique, soit l\'investigateur soit le participant, ne sait pas à quels participants ont été assignées quelles interventions.', 'usage_comment' => '', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1507393851745107970, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Company' => 'National Library of Medicine', 'Definition' => 'A type of masking in which one party involved with the clinical trial, either the investigator or participant, does not know which participants have been assigned which interventions.', 'Industry' => 'Medical devices; Pharmaceutical', 'Part of Speech' => 'noun', 'Product Category' => 'Clinical trials', 'Creation User' => 'elighy', 'Creation Date' => '2012/10/13', 'Term' => 'single blind masking', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'single_blind_masking', )